Contains no animal or human-derived ingredients.
Extracellular vesicles (EVs) *1 StemNavi™, an AOF (Animal Origin Free) culture medium for production. *2 "New product release"
Aiming to advance Regenerative medicine technology
October 8, 2024
ROHTO Pharmaceutical Co., Ltd. (Headquarters: Osaka City, President: Masafumi Sugimoto) will begin selling "StemNavi™ (*2)," an Animal Origin Free (AOF) culture medium for extracellular vesicle (EV) *1 production, on October 9, 2024. This product follows "R:STEM™ (*3)," a mesenchymal stem cell culture medium that has a proven sales record in Japan, and Rohto will continue to contribute to the advancement of Regenerative medicine technology.
*1 Extracellular vesicles (EVs): Extracellular vesicles are a general term for vesicles with a lipid bilayer structure, consisting of growth factors that promote tissue regeneration and exosomes containing intercellular signaling molecules. They are secreted by cells and facilitate intercellular communication.
*2 StemNavi: hMSC expansion AOF w/o Phenol Red
*3 R:Stem：R:STEM Medium for hMSC High Growth
Product launch background
Our company began research into Regenerative medicine in 2013, promoting basic research in Regenerative medicine and basic research in mesenchymal stem cell therapy using AOF (Animal Origin Free) culture medium that does not contain animal or human-derived components. In 2017, we started clinical trials of a human-derived stem cell preparation for liver cirrhosis with Niigata University. Furthermore, in 2020, we launched "R:STEM *3" to allow research institutions and other organizations to widely utilize this AOF culture medium technology.
The "StemNavi *2" being released this time is a product that responds to the recommendation in the "Guidance on Clinical Application of Extracellular Vesicles, etc. (1st Edition)" issued by the Japanese Society Regenerative medicine on April 30, 2024, which states that "Xeno-free culture media that do not contain animal-derived components should be used."
Going forward, our company plans to develop AOF culture media for the global market and expand "StemNavi" into Europe and various Asian countries.
ROHTO Pharmaceutical Co., Ltd. will contribute to creating a world where Regenerative medicine medicine is more accessible and easier to use through its unique technologies that can be applied to Regenerative medicine.
Product overview
| Product name |
hMSC expansion AOF w/o Phenol Red |
| Product features |
- This is an AOF (Animal Origin Free) medium for the production of extracellular vesicles (EVs) *1.
- It is a serum-free medium that does not use animal-derived or human-derived raw materials such as serum, and is composed of chemically defined components.
- Because it does not use animal-derived or human-derived ingredients, the risk of contamination by viruses and other pathogens is reduced.
- It does not contain antibiotics.
- It does not contain phenol red.
- This is a ready-to-use culture medium, so it can be used immediately after thawing.
- The amount of extravalent emissions (EVs) in the culture medium is below the detection limit (ND = Not Detected).
- It promotes the production of EVs and HGF in adipose-derived and umbilical cord-derived hMSCs.
|
| Product form |
Capacity: 500mL
Frozen products: Storage temperature ≦-20℃
*This product is for research use only and cannot be used for diagnostic or clinical purposes. |
| price |
66,000 yen (tax included) |
| Brand site |
https://www.rohto.co.jp/company/business/regenerativemedicine/aof/stemnavi/ |
| release date |
Wednesday, October 9, 2024 |
| Release region |
Japan |
| Manufacturer/Distributor |
ROHTO Pharmaceutical Co., Ltd. |
| Customer Inquiry Contact Information |
ROHTO Pharmaceutical Co., Ltd. Regenerative medicine Business Development Department |
Our AOF medium "R:STEM" became the first in Japan to receive FIRM mark certification (certification number: CAM-0001) on May 17, 2024, based on the ISO 20399 *4 standard.
https://firm-mark.com/
*4 ISO 20399: General requirements for auxiliary materials used in the manufacture of cell therapy and gene therapy products.